Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT05304728
Enrolling by invitation Observational

Sepsis Clinical Decision Support [CDS] Master Enrollment Study Protocol

NCT05304728 · tracked via the Priya Life Science USA tracker
Sponsor
Beckman Coulter, Inc
Phase
Observational
Started
2021-02-15
Last updated
2024-06-21

Condition(s) studied

Severe SepsisSevere Sepsis Without Septic Shock

Study summary

This protocol will collect real-world data retrospectively from the electronic health record (EHR) as data obtained from the delivery of routine medical care to develop a machine learning (ML)-based Clinical Decision Support (CDS) system for severe sepsis prediction and detection.

Eligibility

Sex
ALL
Min age
18 Years
Max age
89 Years
Healthy volunteers
No
Inclusion Criteria: * All races, ages and ethnicities * All patients admitted to the hospital or presenting to the Emergency Department Exclusion Criteria: * Patients not presenting to a hospital setting (e.g. urgent care, outpatient clinic excluded).

Primary outcome measure(s)

  • Severe Sepsis — Within 6 hours from presentation to the emergency department
    Identify patients having Severe Sepsis with the use of electronic health data

Trial sites (10)

FacilityCityRegionStatus
University of California, Irvine Irvine California
Augusta University Medical School Augusta Georgia
Indiana University Health Indianapolis Indiana
University Health/ Truman Medical Center Kansas City Missouri
University of Kansas Medical Center Kansas City Missouri
Hackensack University Medical Center Hackensack New Jersey
WakeMed Health Raleigh North Carolina
University of Cininnati Cincinnati Ohio
MetroHealth Systems Cleveland Ohio
The Ohio State University Columbus Ohio
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05304728 on ClinicalTrials.gov ↗ ← All trials in the USA